Bladder Instillation with Encapsulated-botulinum Toxin A Mucoadhesive Nanoparticles Effectively Ameliorates HCl-induced Hyperactive Bladder in Rats Model

Kuo C1, Mao S2, Chiang B1

1. Cardinal Tien Hospital, 2. Department of Life Science, College of Science, National Taiwan Normal University

KEYWORDS: Animal Study, Painful Bladder Syndrome/Interstitial Cystitis (IC), Basic Science

Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) is defined as persistent or recurrent chronic pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by at least one other urinary symptom such as an urgent need to void or urinary frequency. Diagnosed in the absence of any identifiable pathology which could explain these symptoms. According to AUA guidelines, intravesical treatments with DMSO, heparin, or lidocaine may be administered as second-line treatments, hydrodistension under anesthesia considered as third-line treatment. And in difficult cases of IC/BPS, intravesical (intradetrusor) botulinum toxin A (BTX-A) may be administered as a fourth-line treatment option [1]. Compared to bladder instillation, intravesical injection requires general anesthesia and cystoscopic guided needle injection. Intravesical injection of botox is a more invasive procedure compared to intravesical installation which can be performed under local anesthesia. Thus we invented “encapsulated-botulinum toxin A mucoadhesive nanoparticles (EBMN)”. The nanoparticles can be formed under simply physiological ultrasonic oscillation.

свернуть